Anders Karlén is a professor of Computer-Aided Drug Design at Uppsala University and focuses on hit identification and lead development in antibacterial drug discovery.
His research group studies targets of importance in infectious diseases with a focus on tuberculosis and Gram-negative infections. At Uppsala University, he is the overall medicinal chemistry project leader for drug discovery efforts directed at several different anti-bacterial targets.
Since February 2014, Anders has led the Managing Entity as well as been co-coordinator of the project from the Innovative Medicines Initiative (IMI) entitled European Gram-negative Antibacterial Engine (ENABLE). Since 2019, Anders has also coordinated the project within IMI’s Antimicrobial Resistance (AMR) Accelerator Programme entitled Collaboration for Prevention and Treatment of MDR Bacterial Infections (COMBINE).